Savara shares fall 20% as FDA says it will miss Molgramostim review deadline

Savara (SVRA) shares dropped 20% after the FDA missed its review deadline for molgramostim, a treatment for autoimmune pulmonary alveolar proteinosis. The FDA did not provide a revised date or explain the delay, creating uncertainty for investors. Savara is a clinical-stage biotech company focused on rare respiratory diseases.

Original reporting
Published Nov 20, 2026, 1:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 1:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$SVRA
Bearish
medium confidence
Mentioned
$SVRA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SVRABearishHigh
01

Why it matters

The missed deadline introduces regulatory uncertainty, prompting a sell‑off.

02

Market read

The news directly caused a 20% intraday decline in SVRA, highlighting immediate market impact.

03

What to watch

The company may have received a complete response from the FDA that could shorten the remaining review time.

Relevance 7/10Novelty 8/10Timing: today

Background

Savara is a clinical‑stage biotech focused on rare respiratory diseases; molgramostim is its lead candidate for autoimmune PAP.

Company-level read

Ticker impact

$SVRABearishMedium confidence
Context

FDA missed the PDUFA deadline for Savara's molgramostim, causing a ~20% share drop.

Expected impact

likely pressure as investors price in regulatory delay

Evidence & confidence

The delay adds uncertainty to approval timing and commercial launch, reducing near‑term upside.

Market effects

Potentially dampens sentiment for rare‑disease biotech peers awaiting FDA decisions.

Limited to US biotech sector.

Low; impact confined to Savara and similar small‑cap biotech stocks.

Counterpoint

If the FDA ultimately grants approval, the stock could rebound sharply on the upside.

Key entities

  • Savara

    Biotech developer of molgramostim.

  • FDA

    U.S. agency reviewing the biologics license application.

Related articles

$SVRAMed

FDA to miss deadline on Savara's rare lung disease drug approval

Savara Inc. announced the FDA will miss its November 22 deadline to decide on its rare lung disease drug, molgramostim. The company's shares fell 16% in premarket trading. The FDA did not provide a new decision date, and Savara's application remains under review. Molgramostim is an experimental treatment for autoimmune pulmonary alveolar proteinosis, with no FDA-approved treatments currently available.

$SVRAHighAI 9/10

Why is Savara stock plunging today?

Savara (SVRA) stock fell 21.7% pre-market after the FDA delayed its decision on molgramostim, a treatment for a rare lung disease, without setting a new timeline. The stock had risen to $5.21 ahead of the expected decision. Analysts maintain Buy ratings with targets of $10-$11, but uncertainty looms. The broader market decline also pressured the stock, which traded at $4.08, near its 52-week low.

$SVRAMed

FDA delays decision on Savara’s autoimmune PAP treatment

Savara Inc. (SVRA) reported the FDA delayed its decision on the company's molgramostim treatment for autoimmune PAP, missing the November 2026 target date. The FDA is still reviewing the application and has not set a new timeline. Savara's CEO expressed commitment to working with the agency. Molgramostim is an investigational treatment for a rare lung disease, not yet approved by the FDA.

$SVRAMedAI 8/10

Savara Reports Molgramostim Benefits in Exploratory Lung Study

Savara Inc. (SVRA) reported improvements in lung function and imaging measures in a small subgroup of patients with autoimmune pulmonary alveolar proteinosis (aPAP) treated with molgramostim, according to a retrospective analysis presented at CHEST 2026. The analysis included 11 patients and showed a 12.7 mmHg improvement in the alveolar-arterial oxygen gradient for molgramostim recipients compared to 0.3 mmHg for placebo. The company noted the findings are exploratory and not definitive.